Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study

Background Macular edema is found in more than half of branch retinal vein occlusion (BRVO) cases, leading to visual loss in most of these cases. Intravitreal injection of anti-vascular endothelial growth factor is currently the standard treatment for macular edema due to BRVO (BRVO-ME). The difference in the effects of aflibercept and ranibizumab on the choroid in BRVO-ME is unknown. Therefore, we analyzed the effects of intravitreal injection of ranibizumab and aflibercept on BRVO-ME. Methods We retrospectively observed changes in choroidal thickness in the subfoveal region in 36 patients with BRVO-ME who visited the Department of Ophthalmology at the Juntendo University Urayasu Hospital. The patients were treated with intravitreal injection of aflibercept or ranibizumab and followed up for 12 months or more. Results The observed point bifurcated into the affected and non-affected sides 500 mu m from the fovea. The central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) were 564.2 +/- 268.5 mu m and 228.8 +/- 50.1 mu m, respectively, in the ranibizumab group (16 patients, 16 eyes) and 542.4 +/- 172.5 mu m and 246.1 +/- 59.1 mu m, respectively, in the aflibercept group (20 patients, 20 eyes). The changes in CMT at 12 months were 324.0 +/- 262.6 mu m and 326.55 +/- 187.2 mu m in the ranibizumab and aflibercept groups, respectively, with no significant difference (p = 0.97). Similarly, the changes in SFCT over 12 months were not significant between the groups (ranibizumab, 41.9 +/- 33.0 mu m; aflibercept, 43.8 +/- 43.8 mu m, p = 0.89). Conclusion The effects of ranibizumab and aflibercept on choroidal thickness in BRVO-ME were the same regardless of the site. Although BRVO is a retinal disease, we hope that we can further explore the mechanism of BRVO-ME by observing changes in the choroid in the future.

Automated summary

This study aimed to analyze the effects of intravitreal injection of ranibizumab and aflibercept on macular edema due to branch retinal vein occlusion (BRVO-ME). The results showed no significant difference in the changes of central macular thickness and subfoveal choroidal thickness between the two treatment groups.